SCA
BPMC

Spearhead Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Spearhead Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,990
Closed -$534K – 201
2021
Q4 		$534K Buy
4,990
+244
+5% +$25.5K 0.06% 94
2021
Q3 		$488K Buy
4,746
+242
+5% +$22.5K 0.07% 99
2021
Q2 		$396K Buy
4,504
+545
+14% +$49.9K 0.05% 144
2021
Q1 		$385K Buy
+3,959
New +$395K 0.06% 103

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Spearhead Capital Advisors's BPMC Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 4,990 shares — an estimated $534K sold.

Spearhead Capital Advisors first reported a position in BPMC in Q1 2021 and held it in 4 quarters. The position peaked at $534K in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 4,990 Blueprint Medicines shares in Q1 2022, an estimated $534K.
  • Spearhead Capital Advisors first reported a position in Blueprint Medicines in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Blueprint Medicines position peaked at $534K in Q4 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.